Poland· PL-100274622

Esmya

A ulipristal product containing ulipristalum, registered in Poland by Gedeon Richter Plc.. The same ATC class is registered in 5 of our 19 countries.

ATC G03XB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEsmyaATCG03XB02REGISTER NO.PL-100274622PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Ulipristal is registered in 5 of 19 countries.

Countries holding a registration under ATC G03XB02 (ulipristal), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose

Ulipristal · ATC G03XB02

5 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Italyprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ulipristal costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ulipristal · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • IT Italy$9.03
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ulipristalum
Manufacturer
Gedeon Richter Plc.
Country
Poland (PL)
ATC code
G03XB02
ATC class
Ulipristal
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990958436

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

98 interactions on record for ulipristal.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ulipristal · interactions on record

98 records

  • 2 severe
  • 77 moderate
  • 19 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • VenetoclaxL01XX52severe
  • NaldemedineA06AH05moderate
  • RifaximinA07AA11moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ulipristal in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ulipristal products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Lencya, Ulipristal Acetate Hexal
  • Czechia · Ulipristal Acetate Aristo
  • Germany · Femke, Lencya
  • Denmark · Femke, Ulipristal Acetate Stada
  • Spain · Ulipristal Aristo, Ulipristal Aurovitas
  • Finland · Femke, Ulipristal Acetate Stada
  • France · Ulipristal Acetate Biogaran, Ulipristal Acétate Exeltis
  • United Kingdom (Northern Ireland) · Contrella, Ellaone
  • Greece · Boled, Elperil
  • Ireland · Ulipristal Acetate Rowex
  • Iceland · Ellaone, Ulipristal Acetate Stada
  • Italy · Evante, Lencya
  • Liechtenstein · Ellaone
  • Malta · Ecinq
  • Netherlands · Ecinq, Evante
  • Norway · Ellaone, Femke
  • Portugal · Femke, Ulipristal Aristo
  • Sweden · Ulipristal Acetate Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f339fcf9-f0d7-4624-91d0-6dbbf568250a
GET /v1/drugs/f339fcf9-f0d7-4624-91d0-6dbbf568250a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05909990958436 ¦ Rp ¦ EU/1/12/750/001 ¦ 74766\n28 tabl.\nRp ¦ EU/1/12/750/002 ¦ 90546\n84 tabl.\nRp ¦ EU/1/12/750/004 ¦ 119761\n28 tabl.\nRp ¦ EU/1/12/750/003 ¦ 119762\n30 tabl.\nRp ¦ EU/1/12/750/004 ¦ 119763\n84 tabl.",
  "substance": "Ulipristali acetas 5 mg",
  "common_name": "Ulipristalum",
  "pl_product_id": "100274622",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": "2024-07-18"
}

See everything about ulipristal.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.